Cited by CrossRef (31)
- Tongtong Guo, Qi Wei. Cell Reprogramming Techniques: Contributions to Cancer Therapy. Cellular Reprogramming 2023;25:142

- Massimo Vitale, Monica Parodi. Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?. Vaccines 2021;9:1144

- María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci. Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers 2023;15:1987

- Yang Zhou, Miao Li, Kuangyi Zhou, James Brown, Tasha Tsao, Xinjian Cen, Tiffany Husman, Aarushi Bajpai, Zachary Spencer Dunn, Lili Yang. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy. Cancers 2022;14:2266

- Sandra Charvátová, Benjamin Motais, Justyna Czapla, Tomasz Cichoń, Ryszard Smolarczyk, Zuzana Walek, Sebastian Giebel, Roman Hájek, Juli R. Bagó. Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease. Cells 2023;12:448

- Phatchanat Klaihmon, Xing Kang, Surapol Issaragrisil, Sudjit Luanpitpong. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells. IJMS 2023;24:10508

- Chenxin Wang, Jingjing Liu, Wei Li. ‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cells. Cell Proliferation 2023;56

- Nuno Jorge Lamas, Arnaud Martel, Sacha Nahon-Estève, Samantha Goffinet, Adam Macocco, Corine Bertolotto, Sandra Lassalle, Paul Hofman. Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions. Cancers 2021;14:96

- Michael Swingler, Martina Donadoni, Anna Bellizzi, Senem Cakir, Ilker K. Sariyer. iPSC-derived three-dimensional brain organoid models and neurotropic viral infections. J. Neurovirol. 2023;29:121

- Xinxin Li, Shoubao Ma, Youcai Deng, Ping Yi, Jianhua Yu. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer 2022;21

- Nicholas Boyd-Gibbins, Peter Karagiannis, Do Won Hwang, Shin-Il Kim. iPSCs in NK Cell Manufacturing and NKEV Development. Front. Immunol. 2022;13

- Wang Yaping, Wang Zhe, Chu Zhuling, Li Ruolei, Fan Pengyu, Guo Lili, Ji Cheng, Zhang Bo, Liu Liuyin, Hou Guangdong, Wang Yaoling, Hou Niuniu, Ling Rui. The soldiers needed to be awakened: Tumor-infiltrating immune cells. Front. Genet. 2022;13

- Fatemeh Hosseini, Mohammad Ahmadvand, Roya Karimi, Seyed Asadollah Mousavi, Jafar Ai, Mohsen Nikbakht. Cancer immunotherapy via stem cell-derived NK cells. Immunotherapy 2023;15:963

- Paresh Vishwasrao, Susanta K. Hui, D. Lynne Smith, Vishal Khairnar. Role of NK Cells in Cancer and Immunotherapy. Onco 2021;1:158

- Hong Qin, Changqiao You, Feng Yan, Kefang Tan, Changgen Xu, Rui Zhao, Marlene Davis Ekpo, Songwen Tan. Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper. Front. Oncol. 2022;12

- Chenyu Lin, Mitchell E. Horwitz, Lindsay A. M. Rein. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. IJMS 2022;24:204

- Kyung Cheul Shin. A Novel Metabolic Detour for Pancreatic Cancer Survival. Mol.Cells 2023;46:345

- Tatiana Michel, Markus Ollert, Jacques Zimmer. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. IJMS 2022;23:797

- Fuping Wang, Runting Li, Limeng Zhang, Xiaoning Nie, Linqing Wang, Longxin Chen. Cell Transdifferentiation: A Challenging Strategy with Great Potential. Cellular Reprogramming 2023;25:154

- Wan-Soo Yoon, Dong-Sup Chung. Advanced T and Natural Killer Cell Therapy for Glioblastoma. J Korean Neurosurg Soc 2023;66:356

- Fangjie Wang, Yiqin Cui, Dongmei He, Lisha Gong, Huaping Liang. Natural killer cells in sepsis: Friends or foes?. Front. Immunol. 2023;14

- Marzieh Nikoo, Mohammad Rudiansyah, Dmitry Olegovich Bokov, Nurlan T. Jainakbaev, Wanich Suksatan, Mohammad Javed Ansari, Lakshmi Thangavelu, Supat Chupradit, Amir Zamani, Ali Adili, Navid Shomali, Morteza Akbari. Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances. J Cellular Molecular Medi 2022;26:4137

- Elisaveta Voynova, Damian Kovalovsky. From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. Cells 2021;10:2845

- Wei Du, Lijuan Cui, Jinmei Zhang, Hua Zhang, Rongzhi Liu, Wenling Yang, Yu Zhang. Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell‐derived induced pluripotent stem cell library. FEBS Open Bio 2022;12:1771

- Marta Włodarczyk, Beata Pyrzynska. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer. Cancers 2022;15:117

- Melania Grottoli, Paolo Carrega, Lodovica Zullo, Chiara Dellepiane, Giovanni Rossi, Francesca Parisi, Giulia Barletta, Linda Zinoli, Simona Coco, Angela Alama, Silvia Marconi, Monica Parodi, Paola Orecchia, Sara Bassi, Massimo Vitale, Maria Cristina Mingari, Ulrich Pfeffer, Carlo Genova, Gabriella Pietra. Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. Cancers 2022;14:5046

- Yalan Zhang, Weilin Zhou, Jiangping Yang, Jinrong Yang, Wei Wang. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol 2023;12

- Shuhang Wang, Kun Chen, Yale Jiang, Guo Zhao, Caie Wang, Hong Fang, Qiyu Tang, Chao Sun, Liang Zhang, Haiyang Wu, Li-Feng Zhang, Ning Li. Breaking boundaries: Current progress of anticancer NK cell-based drug development. Drug Discovery Today 2023;28:103436

- Mubin Tarannum, Rizwan Romee, Roman M. Shapiro. Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. Front. Immunol. 2022;13

- Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Özkazanc, Lucia Kučerová, Adil Doganay Duru, Jan Spanholtz, Monica Raimo. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol 2022;15

- Kexin Li, Qingji Huo, Bai-Yan Li, Hiroki Yokota. The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs). Proteomes 2023;11:5
